What is ALX Oncology Holdings Book Value per Share?
ALX Oncology Holdings's book value per share for the quarter that ended in Mar. 2024 was $3.27.
During the past 12 months, ALX Oncology Holdings's average Book Value Per Share Growth Rate was -44.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -29.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of ALX Oncology Holdings was -29.40% per year. The lowest was -29.40% per year. And the median was -29.40% per year.
During the past 6 years, the highest P/B Ratio of ALX Oncology Holdings was 13.05. The lowest was 0.41. And the median was 1.38.
ALX Oncology Holdings Book Value per Share Historical Data
The historical data trend for ALX Oncology Holdings's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ALX Oncology Holdings's Book Value per Share
For the Biotechnology subindustry, ALX Oncology Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALX Oncology Holdings's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where ALX Oncology Holdings's PB Ratio falls into.
ALX Oncology Holdings Book Value per Share Calculation
ALX Oncology Holdings's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
ALX Oncology Holdings (NAS:ALXO) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
ALX Oncology Holdings Book Value per Share Related Terms
Thank you for viewing the detailed overview of ALX Oncology Holdings's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
ALX Oncology Holdings (ALX Oncology Holdings) Business Description
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALXO has been successfully added to your 